Keyword: U.S. Patent & Trademark Office
Alexion's campaign to switch patients from blockbuster Soliris to a follow-up drug has gone according to plan. A new indication will help even more.
Investors are running scared after a patent challenge from Amgen hit Alexion’s bestselling Soliris—but is it that big of a deal?
Amgen persuaded the U.S. patent office to weigh three Alexion patents protecting Soliris, previously considered safe from copycats till 2027.
The government's patents on Gilead's Truvada have made plenty of headlines lately, and that's a distraction, Gilead figures.
With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.
J&J's med should have faced generics years ago, a lawsuit claims, but J&J used underhanded tactics to keep cheaper copycats at bay.
After Biogen's Alzheimer's disease trial failure last month, executives are working to ease investor concern about the company's future.
Allergan took its tribal licensing deal all the way to the Supreme Court, which declined to hear the case.
Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.
An appeals court rejected a motion by J&J to issue an injunction against Zytiga generics, potentially opening the market as a patent case plays out.